Advertisement

Investigational New Drugs

, Volume 18, Issue 4, pp 373–381 | Cite as

Pharmacology of Fluorinated Pyrimidines: Eniluracil

  • Sharyn D. Baker
Article

Abstract

The pharmacological inactivation of dihydropyrimidine dehydrogenase (DPD)represents one strategy to improve 5-FU therapy, which historically hasbeen associated with unpredictable pharmacological behavior andtoxicity. This is principally due to high interpatientdifferences in the activity of DPD, the enzyme that mediates theinitial and rate-limiting step in 5-FU catabolism. Byinactivating DPD and suppressing the catabolism of 5-FU,eniluracil has dramatically altered the pharmacological profileof 5-FU. The maximum tolerated dose of oral 5-FU given with oraleniluracil (1.0 to 25 mg/m2) is substantially lower thanconventional 5-FU doses. In the presence of eniluracil,bioavailability of 5-FU has increased to approximately 100%, thehalf-life is prolonged to 4 to 6 hours, and systemic clearanceis reduced > 20-fold to values comparable the glomerularfiltration rate (46 to 58 mL/min/m2). Renal excretion(∼ 45% to 75%), instead of DPD-related catabolism, is theprincipal route of elimination of oral 5-FU given witheniluracil. Chronic daily administration of oral 5-FU 1.0mg/m2 twice daily with eniluracil 20 mg twice dailyproduces 5-FU steady-state concentrations (8–38 ng/mL) similarto those achieved with protracted intravenous administration onclinically relevant dose-schedules. On a daily × 5regimen, higher 5-FU AUC values are related to neutropenia,whereas elevated 5-FU AUC and steady-state concentrations arerelated to diarrhea when oral 5-FU is given daily with eniluracilon a chronic schedule. The pharmacokinetic behavior of oraleniluracil is similar to that for oral 5-FU. Administration ofeniluracil 10 to 20 mg twice daily completely inactivates DPDactivity both in peripheral blood mononuclear cells and incolorectal tumor tissue, and prolonged inhibition of DPD afterdiscontinuation of eniluracil treatment has been noted. In thepresence of eniluracil, oral administration of 5-FU is feasibleand variation in 5-FU exposure is reduced, with the anticipationof further reduction in variation as dosing guidelines based onrenal function are formulated.

clinical pharmacology dihydropyrimdine dehydrogenase eniluracil oral 5-FU pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 16: 215–237, 1989Google Scholar
  2. 2.
    DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557–2567, 1998Google Scholar
  3. 3.
    Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renee N, Schneider M, Demard F: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 5: 740–744, 1993Google Scholar
  4. 4.
    Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433–5438, 1993Google Scholar
  5. 5.
    Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville 0, Rence N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663–1670, 1995Google Scholar
  6. 6.
    Lu Z, Zhang R, Carpenter JT, Diasio RB: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4: 325–329, 1998Google Scholar
  7. 7.
    Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203–2206, 1987Google Scholar
  8. 8.
    Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients [see comments]. J Clin Oncol 12: 2248–2253, 1994Google Scholar
  9. 9.
    Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, Demard F: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899–2902, 1992Google Scholar
  10. 10.
    Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245–249, 1985Google Scholar
  11. 11.
    Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 81: 4751, 1988Google Scholar
  12. 12.
    Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenctic syndrome. Cancer 68: 499–501, 1991Google Scholar
  13. 13.
    Houyau P, Gay C, Chatelut E, Canal P, Roche H, Milano G: Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency [letter]. J Natl Cancer Inst 85: 1602–1603, 1993Google Scholar
  14. 14.
    Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287–290, 1989Google Scholar
  15. 15.
    Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, et al.: Clinical significance of monitoring serum lcvels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26: 352–354, 1990Google Scholar
  16. 16.
    Grem JL, McAtee N, Balis F, Murphy R, Venzon D, Kramer B, Goldspiel B, Begley M, Allegra CJ: A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72: 663–668, 1993Google Scholar
  17. 17.
    Wihlm J, Leveque D, Klein T: Pharmacodynamics of 5-fluorouracil combined with carboplatin in patients with head and neck cancer. Anticancer Res 14: 2395–2396, 1994Google Scholar
  18. 18.
    Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12: 1291–1295, 1994Google Scholar
  19. 19.
    Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F: Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 13: 1656–1662, 1995Google Scholar
  20. 20.
    Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14: 1663–1671, 1996Google Scholar
  21. 21.
    Spector T, Cao S, Rustum YM, Harrington JA, Porter DJ: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55: 1239–1241, 1995Google Scholar
  22. 22.
    Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluorobeta-alanine. Acta Neuropathol 81: 66–73, 1990Google Scholar
  23. 23.
    Zhang RW, Soong SJ, Liu TP, Barnes S, Diasio SB: Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab Dispos 20: 113–119, 1992Google Scholar
  24. 24.
    Moertel CG: Incidence and significance of multiple primary malignant neoplasms. Ann NY Acad Sci 114: 886–895, 1964Google Scholar
  25. 25.
    Koenig H, Patel A: The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication. Neurology 20: 416, 1970Google Scholar
  26. 26.
    Yeh KH, Cheng AL: High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [letter] [see comments]. Br J Cancer 75: 464–465, 1997Google Scholar
  27. 27.
    Porter DJ, Chestnut WG, Merrill BM, Spector T: Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236–5242, 1992Google Scholar
  28. 28.
    Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243–2248, 1993Google Scholar
  29. 29.
    Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064–11068, 1993Google Scholar
  30. 30.
    Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54: 1507–1510, 1994Google Scholar
  31. 31.
    Arellano M, Malet-Martino M, Martino R, Spector T: 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Br J Cancer 76: 1170–1180, 1997Google Scholar
  32. 32.
    Adams ER, Leffert JJ, Craig DJ, Spector T, Pizzorno G: In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy. Cancer Res 59: 122–127, 1999Google Scholar
  33. 33.
    Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085–3096, 1996Google Scholar
  34. 34.
    Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK: Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 18: 915–926, 2000Google Scholar
  35. 35.
    Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA, 3rd: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16: 1450–1457, 1998Google Scholar
  36. 36.
    Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201, 1990Google Scholar
  37. 37.
    Takimoto CH, Yee LK, Venzon DJ, Schuler B, Grollman F, Chabuk C, Hamilton M, Chen AP, Allegra CJ, Grem JL: High inter-and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res 5: 1347–1352, 1999Google Scholar
  38. 38.
    Yan J, Yan L, Suttle AB, Mangum S, Lucas VS, Diasio R: A preliminary pharmacokinetic and metabolic evaluation of 5-fluorouracil (5TU) in the presence of oral eniluracil. Proc ASCO 18: 173a, 1999Google Scholar
  39. 39.
    Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE: Phase I study of enifuracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5: 291–298, 1999Google Scholar
  40. 40.
    Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Jr., Grem JL, Allegra G, Diasio RB, Chu E: Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477–481, 1996Google Scholar
  41. 41.
    Spector T, Porter WT, Nelson J, Baccanari DP, Davis ST, Almind MR, Khor S-P, Amyx H, Cao S, Rusturn YM: 5-ethynyluracil (776C85), amodulator of the therapeutic activity of 5-fluorouracil. Drugs of the Future 19: 565–571, 1994Google Scholar
  42. 42.
    Ahmed FY, Johnston SJ, Cassidy J, O'Kelly T, Binnie N, Murray GI, van Gennip AH, Abeling NG, Knight S, McLeod HL: Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 17: 2439–2445, 1999Google Scholar
  43. 43.
    Grem J, Harold N, Bi D, Takimoto C, Zenko S, Hamilton M, Chen A, Monahan B, Quinn M, Morrison G, Nguyen D, Shapiro J: A phase I & pharmacologic (PK/PD) study of weekly oral fluorouracil (FUra) given with eniluracil (GW 776C85) & leucovorin (LV) in patients (pts) with solid tumors. Proc ASCO 18: 173a, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Sharyn D. Baker
    • 1
  1. 1.The Johns Hopkins Oncology CenterBaltimoreUSA

Personalised recommendations